Obstrução de vias lacrimais associada ao tratamento radioiodoterápico de carcinoma de tireoide

Fonseca, Fabricio Lopes da; Lunardelli, Patrícia; Matayoshi, Suzana

doi:10.1590/s0004-27492012000200005

Cited by 22 publications

(12 citation statements)

References 16 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reason for this can be explained by the fact that NLDO is possibly a chronic radiation-induced injury that progresses over a period of time. 16 The DCR success rate of 78.9% in our cohort is consistent with the findings of Fonseca et al 6 However, the endoscopic endonasal DCR success rate of 60% is much inferior to that reported in the literature, which warrants more personnel training in this area in our region. 17 …”

Section: Discussionsupporting

confidence: 89%

“…In our cohort, the frequency of NLDO of 2.2% is consistent with other reported results ( Table 2 ). 6 – 10 The incidence rate of NLDO in the general population is lacking, despite a detailed medical literature search. In the majority of cases, the diagnosis is made upon the basis of spontaneous reporting of epiphora by the patients.…”

Section: Discussionmentioning

confidence: 99%

“…In the majority of cases, the diagnosis is made upon the basis of spontaneous reporting of epiphora by the patients. 6 This diagnostic delay leads to complete stenosis of the nasolacrimal ducts, and thus renders these patients to aggressive treatment. 6 In the clinical setting, the Jones fluorescein dye test is of significant value in NLDO patients.…”

Section: Discussionmentioning

confidence: 99%

“… 6 This diagnostic delay leads to complete stenosis of the nasolacrimal ducts, and thus renders these patients to aggressive treatment. 6 In the clinical setting, the Jones fluorescein dye test is of significant value in NLDO patients. One Australian study has demonstrated that a negative single-drop Jones fluorescein dye test is also predictive of symptomatic improvement after DCR in patients with NLDO.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Al‐Qahtani¹,

Asiri²,

Tunio³

et al. 2014

OPTH

View full text Add to dashboard Cite

BackgroundRadioactive iodine 131 (131I) therapy has long been used in the treatment of differentiated thyroid cancers (DTC). While salivary and lacrimal glandular complications secondary to 131I therapy are well documented, there is little in the literature addressing nasolacrimal duct obstruction (NLDO). We aimed to evaluate the frequency of 131I therapy-acquired NLDO, its correlation to 131I therapy doses, and the surgical treatment outcome of this rare side effect.MethodsFrom 2000–2012, a retrospective review of 864 among 1,192 patients with confirmed DTC who were treated with 131I therapy was performed to examine the frequency of NLDO, its causative factors, as well as imaging, surgical intervention, and outcomes.ResultsNineteen (2.2%) patients were identified with NLDO. The mean age was 51.9±10.5 years (range: 39–72 years). Fifteen (78.9%) were female and four were male (21.1%). The mean individual 131I doses were 311.1±169.3 millicurie (mCi) (range: 150–600 mCi). The mean duration between the date of 131I therapy and the occurrence of NLDO was 11.6±4.1 months (range: 6.5–20). Fourteen (73.7%) patients had bilateral epiphora. Computed tomography dacryography allowed for the detection of all NLDO. Eighteen (94.7%) patients underwent dacryocystorhinostomy. Complete recovery was obtained in 14 (73.7%) patients. Age >45 years and 131I therapy doses >150 mCi were significantly correlated with NLDO (P=0.02 and P=0.03, respectively).ConclusionNLDO is an underestimated complication of 131I therapy in DTC patients. Clinicians should be aware of this rare complication for prompt intervention.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Al‐Qahtani¹,

Asiri²,

Tunio³

et al. 2014

OPTH

View full text Add to dashboard Cite

show abstract

“…3,4 Well-described ocular side effects include dry eye symptoms, 5–7 dacryocystitis, and epiphora due to nasolacrimal duct obstruction. 8,9 The proposed mechanism for the development of nasolacrimal obstruction has been described as absorption of the radioactive material by the sodium-iodide transporters (NIS) located in the stratified columnar epithelial cells of the lacrimal sac and duct, causing subsequent inflammation, which leads to fibrosis. 7 Most of these patients ultimately require a dacryocystorhinostomy to alleviate the epiphora and recurrent infections.…”

mentioning

confidence: 99%

Topical Application of Perchlorate: A Toxicity Study in Rats

Ulloa-Padilla,

Burkat,

Morgenstern

2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: To investigate the ocular safety profile of topical perchlorate as a potential preventive treatment for nasolacrimal obstruction associated with excessive use of radioactive iodine therapy. Methods: Nine Wistar male rats (18 eyes) were randomly assigned to receive an ocular application (topical eye drop on the OD, 3 times a day for 5 days) consisting of either: 1) sterile saline solution, 2) 30 mg/ml NaClO4 or 3) 30 mg/ml KClO4. The rat eyes were examined daily for corneal cloudiness/clarity, discharge, mucous secretions, conjunctival injection, eyelid erythema, and/or changes in behavior. Seven days after the first dose, the rats were euthanized and OU were harvested, fixed, embedded in paraffin, and stained with H&E and Masson’s trichrome using standard techniques. Results: The data collected over the 7 days revealed no behavior changes or ocular complications in any of the 3 study groups. Pathologic analysis of the corneas revealed normal findings on all groups without signs of inflammation, fibrosis, or any other abnormality, and no difference between the treated and control eyes. Conclusions: The findings of this study suggest that the use of topical perchlorate is safe to use on eyes in high concentrations. The efficacy of this compound in minimizing fibrosis of the nasolacrimal sac and duct warrants further study.

show abstract

Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Obstrução de vias lacrimais associada ao tratamento radioiodoterápico de carcinoma de tireoide

Cited by 22 publications

References 16 publications

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases

Topical Application of Perchlorate: A Toxicity Study in Rats

Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study

Contact Info

Product

Resources

About